A study of the role of noradrenaline in behavioural changes produced in the rat by psychotomimetic drugs
British Journal of Pharmacology February 1, 1969 DOI: 10.1111/j.1476-5381.1969.tb07983.x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | psilocybin reserpine |
| Topics | Psilocybin |
| Keywords | Reserpine Psychotomimetic Hallucinogen Avoidance response Pharmacology Endocrinology |
| Citations | 40 |
| Key findings | LSD-25, psilocybin, and JB-329 reduce hypothalamic noradrenaline and alter conditioned avoidance response acquisition, with LSD-25 and psilocybin retarding and JB-329 enhancing it, and the drugs' behavioral and neurochemical effects show different time courses and dose thresholds. |
Abstract
LSD‐25, psilocybin and JB‐329 reduced the noradrenaline content of the rat hypothalamus. All three drugs affected the acquisition of a conditioned avoidance response, LSD‐25 and psilocybin retarding and JB‐329 enhancing the acquisition. With the exception of JB‐329, doses affecting the acquisition of a conditioned avoidance response were lower than those required to decide hypothalamic noradrenaline concentrations. The time of peak drug effect on the acquisition of a conditioned avoidance response occurred approximately 1.5 hr after injection as opposed to 3 hr in the case of noradrenaline content. The amount of LSD‐25, psilocybin and JB‐329 necessary to elicit gross behavioural excitation was similar to the dose producing noradrenaline depletion. Here also the peak behavioural effect was detected earlier. Pretreatment with reserpine and α‐MT had no effect on the intensity of gross behavioural excitation induced by LSD‐25 and psilocybin but shortened the duration of the response. The excitation induced by JB‐329 was abolished by reserpine pretreatment and was markedly reduced both in intensity and duration by the prior injection of α‐MT.
Comparable studies
Other preclinical and animal studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice Mice | 2021 | Experimental study | |
| Psychedelics reopen the social reward learning critical period Mice | 2023 | Experimental study in mice | |
| Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. C57BL/6J mice | 2020 | Experimental study with dose-response experiments | |
| Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning Mice | 2013 | Experimental study |
Citations in the library
Cited by 8
- Psilocybin – Summary of knowledge and new perspectives European Neuropsychopharmacology December 17, 2013
- Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol Therapeutic Drug Monitoring July 12, 2013
- The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat Frontiers in Behavioral Neuroscience May 16, 2014
- Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents Neuroscience & Biobehavioral Reviews September 20, 2024
- Utility of preclinical models in the study of psilocybin – A comprehensive review Neuroscience & Biobehavioral Reviews January 13, 2023
and 3 more in the library